Life Science Investing NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries
Life Science Investing I-MAB Transitions to NovaBridge Biosciences with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform
Life Science Investing I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025
Life Science Investing I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments
Life Science Investing I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee
LaFleur Minerals Closes $1.66 Million Flow-Through Offering to Advance Drilling and PEA-Related Work at its Swanson Gold Deposit
